Terms: = Pancreatic cancer AND TRA
27 results:
1. A targetable pathway to eliminate tra-1-60+/tra-1-81+ chemoresistant cancer cells.
Tan L; Duan X; Mutyala P; Zhou T; Amin S; Zhang T; Herbst B; Askan G; Itkin T; Xiang Z; Michelassi F; Lieberman MD; Iacobuzio-Donahue CA; Leach SD; Evans T; Chen S
J Mol Cell Biol; 2023 Nov; 15(6):. PubMed ID: 37327088
[TBL] [Abstract] [Full Text] [Related]
2. KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.
Zhang H; Liu X; Chen Y; Xu R; He S
Biomed Res Int; 2022; 2022():1556485. PubMed ID: 36212716
[TBL] [Abstract] [Full Text] [Related]
3. Colon adenocarcinoma-derived cells that express induced-pluripotent stem cell markers possess stem cell function.
Munro MJ; Peng L; Wickremesekera SK; Tan ST
PLoS One; 2020; 15(5):e0232934. PubMed ID: 32428045
[TBL] [Abstract] [Full Text] [Related]
4. Detecting tra-1-60 in cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent.
White JM; Kuda-Wedagedara AN; Wicker MN; Spratt DE; Schopperle WM; Heath E; Viola NT
Mol Pharm; 2020 Apr; 17(4):1139-1147. PubMed ID: 32069422
[TBL] [Abstract] [Full Text] [Related]
5. Regulation of pancreatic cancer traIL resistance by protein O-GlcNAcylation.
Yang SZ; Xu F; Yuan K; Sun Y; Zhou T; Zhao X; McDonald JM; Chen Y
Lab Invest; 2020 May; 100(5):777-785. PubMed ID: 31896813
[TBL] [Abstract] [Full Text] [Related]
6. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract] [Full Text] [Related]
7. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Xu F; Sun Y; Yang SZ; Zhou T; Jhala N; McDonald J; Chen Y
Int J Cancer; 2019 Jul; 145(2):474-483. PubMed ID: 30614530
[TBL] [Abstract] [Full Text] [Related]
8. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract] [Full Text] [Related]
9. The novel traIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
[TBL] [Abstract] [Full Text] [Related]
10. [La combinazione di gemcitabina e oxaliplatino (GEMOX) nel trattamento del carcinoma pancreatico in fase avanzata di malattia: le notizie sulla mia morte sono state esagerate?].
Giuliani J; Bonetti A
Recenti Prog Med; 2017 Dec; 108(12):521-527. PubMed ID: 29297902
[TBL] [Abstract] [Full Text] [Related]
11. The CA19-9 and Sialyl-tra Antigens Define Separate Subpopulations of pancreatic cancer Cells.
Barnett D; Liu Y; Partyka K; Huang Y; Tang H; Hostetter G; Brand RE; Singhi AD; Drake RR; Haab BB
Sci Rep; 2017 Jun; 7(1):4020. PubMed ID: 28642461
[TBL] [Abstract] [Full Text] [Related]
12. A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of tra-8/DR5 Oligomers Predicts tra-8 Therapeutic Efficacy in Breast and pancreatic cancer Mouse Models.
Kim H; Buchsbaum DJ; Zinn KR
Mol Imaging Biol; 2016 Jun; 18(3):325-33. PubMed ID: 26552657
[TBL] [Abstract] [Full Text] [Related]
13. Calmodulin antagonists promote tra-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract] [Full Text] [Related]
14. Association between Variants in Atopy-Related Immunologic Candidate Genes and pancreatic cancer Risk.
Cotterchio M; Lowcock E; Bider-Canfield Z; Lemire M; Greenwood C; Gallinger S; Hudson T
PLoS One; 2015; 10(5):e0125273. PubMed ID: 25945796
[TBL] [Abstract] [Full Text] [Related]
15. Expression of the clustered NeuAcα2-3Galβ O-glycan determines the cell differentiation state of the cells.
Higashi K; Asano K; Yagi M; Yamada K; Arakawa T; Ehashi T; Mori T; Sumida K; Kushida M; Ando S; Kinoshita M; Kakehi K; Tachibana T; Saito K
J Biol Chem; 2014 Sep; 289(37):25833-43. PubMed ID: 25074924
[TBL] [Abstract] [Full Text] [Related]
16. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Forero-Torres A; Infante JR; Waterhouse D; Wong L; Vickers S; Arrowsmith E; He AR; Hart L; Trent D; Wade J; Jin X; Wang Q; Austin T; Rosen M; Beckman R; von Roemeling R; Greenberg J; Saleh M
Cancer Med; 2013 Dec; 2(6):925-32. PubMed ID: 24403266
[TBL] [Abstract] [Full Text] [Related]
17. PARP-1 regulates resistance of pancreatic cancer to traIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract] [Full Text] [Related]
18. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract] [Full Text] [Related]
19. Defined factors induce reprogramming of gastrointestinal cancer cells.
Miyoshi N; Ishii H; Nagai K; Hoshino H; Mimori K; Tanaka F; Nagano H; Sekimoto M; Doki Y; Mori M
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):40-5. PubMed ID: 20018687
[TBL] [Abstract] [Full Text] [Related]
20. Embryonic stem cell-like cells derived from adult human testis.
Mizrak SC; Chikhovskaya JV; Sadri-Ardekani H; van Daalen S; Korver CM; Hovingh SE; Roepers-Gajadien HL; Raya A; Fluiter K; de Reijke TM; de la Rosette JJ; Knegt AC; Belmonte JC; van der Veen F; de Rooij DG; Repping S; van Pelt AM
Hum Reprod; 2010 Jan; 25(1):158-67. PubMed ID: 19815622
[TBL] [Abstract] [Full Text] [Related]
[Next]
